TRAILreceptortargeted
TRAIL receptor targeted therapy refers to a class of drugs designed to activate the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor pathway, which can selectively induce apoptosis, or programmed cell death, in cancer cells while sparing normal cells. TRAIL, also known as Apo2L, is a transmembrane protein that binds to specific death receptors on the cell surface, including TRAIL-R1 (DR4) and TRAIL-R2 (DR5). Upon binding, these receptors form a death-inducing signaling complex (DISC) that triggers a cascade of events leading to caspase activation and ultimately apoptosis.
Many cancer cells exhibit an upregulation of TRAIL death receptors, making them particularly susceptible to TRAIL-mediated
Despite the promising preclinical results, the clinical translation of TRAIL receptor targeted therapy has faced challenges.